Skip to main content
. 2020 Mar 10;8(5):404–406. doi: 10.1093/gastro/goaa005

Figure 1.

Figure 1.

Endoscopic improvement after vedolizumab therapy in a patient with chronic granulomatous disease-related inflammatory bowel disease. (A) Erythema, friability, and ulceration prior to vedolizumab therapy. (B) Mucosal erythema and granularity after vedolizumab therapy.